He learned to read a mass spectrum before he learned to read a term sheet. Now he does both - and runs a company betting that the next cancer therapy comes off the shelf.
On March 13, 2023, Kumar Srinivasan walked into the corner office at Wugen, a clinical-stage biotech tucked into the 4260 Forest Park Avenue corridor in St. Louis. The company had a proprietary platform, two lead assets with hard-to-pronounce names, and a thesis that cuts against twenty years of cell therapy orthodoxy: that the most powerful cancer cell therapies should not have to be built one patient at a time.
That is the whole pitch of off-the-shelf, or allogeneic, therapy. Conventional CAR-T is bespoke - a patient's own cells are extracted, re-engineered, and returned, a process that is brilliant and slow and expensive. Wugen's wager, and now Srinivasan's, is that donor-derived memory NK and CAR-T cells can be manufactured ahead of time, frozen, and dosed on demand. The two assets carrying that bet are WU-CART-007, a CD7-targeted CAR-T for T-cell malignancies, and WU-NK-101, the first candidate out of the company's memory NK cell platform.
When he arrived, Srinivasan kept the message simple. "I am thrilled to be joining Wugen at this exciting time for the company," he said, naming WU-NK-101 and WU-CART-007 as the reasons. It reads like boilerplate until you notice what he chose to anchor to: not the platform, not the science generally, but two specific programs and the patients waiting on them.
Before the CEO title, before the deals, there was benchwork. Srinivasan earned a dual B.S./M.S. in chemistry from the University of Madras, then crossed an ocean for a Ph.D. in organic chemistry at Case Western Reserve University. He did postdoctoral research at Caltech. That is a pedigree built for a lifetime of pipetting and publishing - the exact opposite of what he ended up doing.
Somewhere along the way he picked up an MBA in finance and strategy from the University of Chicago's Booth School of Business, and the trajectory bent. He stopped making molecules and started making the agreements that move them. Earlier roles took him through TorreyPines Therapeutics, the Germany-based Vivoryon (then Probiodrug AG), and Wyeth. The through-line was business development: figuring out which assets are worth buying, which are worth selling, and what each is really worth.
Then came AstraZeneca, where he spent nine-plus years as vice president and global head of business development for the Biopharmaceuticals unit. He owned in- and out-licensing, collaborations, and alliance management across multiple therapeutic areas. When COVID-19 hit, he led the licensing work behind AstraZeneca's vaccine and monoclonal antibody programs - some of the most-watched deals of the pandemic, negotiated under a clock that did not stop.
It is worth pausing on what that decade taught him. Big Pharma business development is a particular kind of education: you learn to value an asset you did not invent, to negotiate with partners who may also be rivals, and to keep alliances alive long after the ink dries. Those are exactly the muscles a small company needs in a CEO - because a 52-person biotech survives on partnerships it cannot build alone. Wugen's manufacturing arrangement with Cellipont Bioservices for clinical-scale production of its off-the-shelf CAR-T cells is precisely the sort of deal his career was built to close.
His most recent act before Wugen was the one that gets repeated in introductions. As executive vice president and chief business officer at Turning Point Therapeutics, Srinivasan ran the partnering strategy for the company's lead program, repotrectinib. That strategy ended in an acquisition by Bristol Myers Squibb valued at roughly $4.1 billion. It is the kind of outcome most biotech executives spend an entire career chasing and never catch.
So the obvious question about Wugen is the interesting one: how do you follow that? Not by chasing another exit on day one, but by doing the unglamorous work of moving programs through the clinic. In November 2024, Wugen initiated a pivotal trial for WU-CART-007 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma - cancers with brutal odds and few options.
Wugen is not a coastal biotech that happens to have a Midwest address. It was incubated in the St. Louis innovation ecosystem and grew up in the orbit of BioGenerator, the region's life-science investor and company-builder. Its first NK cell therapy trial - the one that put WU-NK-101 into patients with acute myeloid leukemia - was a milestone not just for the company but for a city trying to prove it can build frontier cell therapy outside Boston and the Bay. Srinivasan inherited that civic weight along with the pipeline.
The scientific contrarianism runs deeper than geography. Most of the cell-therapy field has poured its energy into autologous CAR-T - powerful, approved, and logistically punishing. Wugen leans the other way, toward donor-derived cells and, notably, toward natural killer cells, an arm of the immune system that does not require the same precise matching that T cells do. The company's memory NK approach, built on its Moneta platform, tries to coax NK cells into a longer-lived, more potent state. When Srinivasan calls WU-NK-101 "the first therapeutic candidate from our memory NK cell platform to enter the clinic," he is marking the moment a laboratory idea became a clinical reality.
There is a quiet advantage in a CEO who can actually read the data. A pure financier sees a pipeline as a spreadsheet of probabilities. Srinivasan, who once measured reactions for a living, sees the assays underneath. When he says WU-NK-101 could be explored "as a salvage therapy for patients who have failed or are resistant to immune checkpoint blockade treatment," that is not a slide deck talking - it is someone who understands what failure of checkpoint blockade means biologically, and where an NK cell might slip in.
That dual fluency is the rare thing here. The chemistry gives him the why; the Booth MBA and two decades of deals give him the how-much and the who-pays. Most biotech leaders have one of those instruments well-tuned. Srinivasan plays both, which is what you want at a company whose entire premise - off-the-shelf cell therapy at scale - lives or dies on getting both the science and the economics right at the same time.
Wugen now reports roughly $323 million in total funding, with a Series C closing in 2025. The company runs lean - about 52 employees by recent count - which means the distance between the CEO's decisions and the lab's reality is short. In a 52-person company, the person at the top is not insulated from the work. That suits a leader who spent the first chapter of his career inside the experiment, not above it.
Read the bullet points and you get a tidy arc: chemistry, business development, a big exit, a CEO chair. Read between them and you see a pattern of crossing borders that most people never cross. He moved from India to the United States for graduate school. He moved from the lab to the deal table. He worked at a German biotech, a multinational pharma, and a lean West Coast oncology company, and then took a job in Missouri. Each move traded comfort for range, and range is the rarest currency in an industry that rewards specialists.
It also explains why he fits Wugen specifically. A company selling a contrarian manufacturing thesis needs a leader who is comfortable being early and comfortable explaining himself to skeptics - investors, regulators, oncologists who have seen promising platforms fizzle. The Booth training gives him the vocabulary of capital. The Caltech years give him the credibility of the bench. Together they let him stand in front of two very different rooms and be believed in both.
The bet is not yet won. Pivotal trials are pivotal precisely because they can go either way. But the shape of the wager is clear, and so is the person holding it: a chemist who learned to close, a closer who never stopped reading the data, running a St. Louis company that wants to make advanced cancer therapy as available as a vial in a freezer.
I am thrilled to be joining Wugen at this exciting time for the company.
Receiving breakthrough therapy designation from the FDA is a significant milestone and a testament to the potential of our therapy to address a critical unmet medical need.
The data we reported from our Phase 1/2 study suggests it has the potential to set a new standard of care for relapsed or refractory T-ALL/LBL.
Our goal is to deploy our memory NK cell platform to deliver next-generation, best-in-class allogeneic therapies to transform cancer care, including solid tumors.
Off-the-shelf ambition, benchtop fluency — the file on Kumar Srinivasan.